Albumin Infusion May Improve the Prognosis of Critical COVID-19 Patients with Hypoalbuminemia in the Intensive Care Unit: A Retrospective Cohort Study

Background The coronavirus disease 2019 (COVID-19) pandemic has caused enormous mortality worldwide. Low albumin level is a risk factor for increasing mortality among patients in the intensive care unit (ICU). This study investigated the effect of albumin infusion on critical COVID-19 patients with hypoalbuminemia. Methods A total of 114 COVID-19 ICU patients with hypoalbuminemia were recruited from Wuhan Leishenshan Hospital and Zhongnan Hospital of Wuhan University. Clinical features and laboratory variables were collected through electronic medical records. The cohorts were divided into two groups: albumin infusion and non-albumin infusion. Propensity-matched analysis was used to compare patients who received albumin to controls. Statistical analyses were used to investigate the survival time and inflammation-related blood biomarkers between groups. Results Lactate dehydrogenase, interleukin (IL)-6, IL-2 receptor, and IL-8 levels were significantly downregulated in the albumin infusion group. Significant upregulations of lymphocyte counts and IL-10 were found in the albumin infusion group. There was a negative association between albumin level and D-dimer or procalcitonin levels after treatment. The albumin infusion group had a significantly longer survival time and shorter hospitalization time than control patients. Notably, a 1g increase in albumin level reduced the risk of death by approximately 7.3% after adjusting for age and sex. Patients with increased albumin levels after treatment had better prognoses than those without. Conclusion Albumin administration can regulate COVID-19-related biomarkers and reduce the risk of death in critical patients with hypoalbuminemia. Clinicians should pay more attention to these risk factors. Targeted clinical interventions should be implemented to minimize the negative impacts of hypoalbuminemia and improve disease outcomes.

[1]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[2]  Lovorka Đerek,et al.  Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients , 2022, Wiener klinische Wochenschrift.

[3]  A. Kristof,et al.  Albumin and fibrinogen kinetics in sepsis: a prospective observational study , 2021, Critical Care.

[4]  I. Kostić,et al.  Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study , 2021, Emergency Medicine Journal.

[5]  Ying Zhang,et al.  Hypoalbuminemia – An Indicator of the Severity and Prognosis of COVID-19 Patients: A Multicentre Retrospective Analysis , 2021, Infection and drug resistance.

[6]  C. Signori,et al.  Albumin Oxidation Status in Sepsis Patients Treated With Albumin or Crystalloids , 2021, Frontiers in Physiology.

[7]  W. Feaster,et al.  Long-term effects of malnutrition on severity of COVID-19 , 2021, Scientific Reports.

[8]  Jinrong Fu,et al.  The signal pathways and treatment of cytokine storm in COVID-19 , 2021, Signal Transduction and Targeted Therapy.

[9]  A. Mui,et al.  Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? , 2021, Frontiers in Immunology.

[10]  K. Miyaji,et al.  Serum Albumin Redox States: More Than Oxidative Stress Biomarker , 2021, Antioxidants.

[11]  F. Petersen,et al.  High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19 , 2021, Frontiers in Immunology.

[12]  N. Grandvaux,et al.  ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities , 2020, eLife.

[13]  G. D'offizi,et al.  Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome , 2020, Cell Death & Disease.

[14]  H. Mansouritorghabeh,et al.  D-dimer level in COVID-19 infection: a systematic review , 2020, Expert review of hematology.

[15]  A. Agrawal,et al.  Complement Activation by C-Reactive Protein Is Critical for Protection of Mice Against Pneumococcal Infection , 2020, Frontiers in Immunology.

[16]  R. Fiorotto,et al.  Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis , 2020, Hepatology.

[17]  F. Cipollone,et al.  IS ALBUMIN PREDICTOR OF MORTALITY IN COVID-19 ? , 2020, Antioxidants & redox signaling.

[18]  Chaofei Han,et al.  Procalcitonin levels in COVID-19 patients , 2020, International Journal of Antimicrobial Agents.

[19]  S. Antinori,et al.  Role of serum albumin and proteinuria in patients with SARS‐CoV‐2 pneumonia , 2020, International journal of clinical practice.

[20]  Jiaofeng Huang,et al.  Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity , 2020, Journal of medical virology.

[21]  M. Gonzalez‐Freire,et al.  Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study , 2020, medRxiv.

[22]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[23]  Tao Li,et al.  Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China , 2020, European Journal of Clinical Nutrition.

[24]  K. Cárdenas-Jaén,et al.  Increased Amylase and Lipase in Patients With COVID-19 Pneumonia: Don't Blame the Pancreas Just Yet! , 2020, Gastroenterology.

[25]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[26]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[27]  P. Pelosi,et al.  Effects of crystalloid, hyper-oncotic albumin, and iso-oncotic albumin on lung and kidney damage in experimental acute lung injury , 2019, Respiratory Research.

[28]  B. Tingstedt,et al.  Albumin infusion rate and plasma volume expansion: a randomized clinical trial in postoperative patients after major surgery , 2019, Critical Care.

[29]  R. Petterle,et al.  Procalcitonin, C-Reactive Protein, Albumin, and Blood Cultures as Early Markers of Sepsis Diagnosis or Predictors of Outcome: A Prospective Analysis , 2019, Clinical pathology.

[30]  Hideaki Shimizu,et al.  Low serum albumin as a risk factor for infection-related in-hospital death among hemodialysis patients hospitalized on suspicion of infectious disease: a Japanese multicenter retrospective cohort study , 2018, Renal Replacement Therapy.

[31]  J. Laukkanen,et al.  Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein , 2018, Annals of medicine.

[32]  M. Mohsenzadegan,et al.  The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells , 2017, Cell Communication and Signaling.

[33]  Y. Song,et al.  Can Serum Albumin Level and Total Lymphocyte Count be Surrogates for Malnutrition to Predict Wound Complications After Total Knee Arthroplasty? , 2016, The Journal of arthroplasty.

[34]  H. V. Straaten,et al.  Albumin rather than C-reactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever , 2015, BMC Pulmonary Medicine.

[35]  G. Martin,et al.  Albumin administration in the acutely ill: what is new and where next? , 2014, Critical Care.

[36]  J. Schmitt,et al.  Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis , 2014, Critical Care.

[37]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[38]  V. Boddi,et al.  Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. , 2006, World journal of gastroenterology.

[39]  D. Benjamin,et al.  Infection and Drug Resistance , 2022 .